SCM
XLO icon

Soleus Capital Management’s Xilio Therapeutics XLO Stock Holding History

Soleus Capital Management’s Portfolio XLO Stock Details XLO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-16,210
Closed -$479K – 104
2023
Q3 		$479K Hold
16,210
– – 0.04% 89
2023
Q2 		$595K Hold
16,210
– – 0.07% 93
2023
Q1 		$719K Hold
16,210
– – 0.07% 74
2022
Q4 		$610K Sell
16,210
-16,194
-50% -$546K 0.09% 67
2022
Q3 		$1.32M Hold
32,404
– – 0.18% 66
2022
Q2 		$1.32M Sell
32,404
-1,703
-5% -$90.1K 0.21% 65
2022
Q1 		$3.38M Hold
34,107
– – 0.44% 47
2021
Q4 		$7.64M Buy
+34,107
New +$8.13M 0.76% 30

Other funds holding XLO

BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $790M AUM 223.66% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return
TPC
Takeda Pharmaceutical Company Tokyo, Japan $16.4M AUM 195.92% 1-Year Est. Return
RVM
RiverVest Venture Management St. Louis, Missouri $6.84M AUM 7.71% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Soleus Capital Management's XLO Position: Q4 2023 in Review

Soleus Capital Management sold out of Xilio Therapeutics (XLO) in Q4 2023, closing a stake of 16,210 shares — an estimated $479K sold.

Soleus Capital Management first reported a position in XLO in Q4 2021 and held it in 8 quarters. The position peaked at $7.64M in Q4 2021. 33 funds tracked by Wall St. Rank hold XLO as of Q4 2023.

  • Soleus Capital Management reported no remaining Xilio Therapeutics position as of Q4 2023 after selling out during the quarter.
  • Soleus Capital Management sold 16,210 Xilio Therapeutics shares in Q4 2023, an estimated $479K.
  • Soleus Capital Management first reported a position in Xilio Therapeutics in Q4 2021 and held it in 8 quarters.
  • Soleus Capital Management's Xilio Therapeutics position peaked at $7.64M in Q4 2021.
  • 33 funds tracked by Wall St. Rank held Xilio Therapeutics as of Q4 2023.

Based on Soleus Capital Management's 13F filing for Q4 2023, filed 14 Feb 2024.